Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A cross-sectional and longitudinal analysis of pre-diagnostic blood plasma biomarkers for early detection of pancreatic cancer
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology. Umeå University, Faculty of Medicine, Wallenberg Centre for Molecular Medicine at Umeå University (WCMM).
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Surgery.ORCID iD: 0000-0001-7426-6889
Umeå University, Faculty of Science and Technology, Department of Chemistry.ORCID iD: 0000-0001-8357-5018
Umeå University, Faculty of Medicine, Wallenberg Centre for Molecular Medicine at Umeå University (WCMM). Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Surgery.
Show others and affiliations
2022 (English)In: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 23, no 21, article id 12969Article in journal (Refereed) Published
Abstract [en]

Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer death that typically presents at an advanced stage. No reliable markers for early detection presently exist. The prominent tumor stroma represents a source of circulating biomarkers for use together with cancer cell-derived biomarkers for earlier PDAC diagnosis. CA19-9 and CEA (cancer cell-derived biomarkers), together with endostatin and collagen IV (stroma-derived) were examined alone, or together, by multivariable modelling, using pre-diagnostic plasma samples (n = 259 samples) from the Northern Sweden Health and Disease Study biobank. Serial samples were available for a subgroup of future patients. Marker efficacy for future PDAC case prediction (n = 154 future cases) was examined by both cross-sectional (ROC analysis) and longitudinal analyses. CA19-9 performed well at, and within, six months to diagnosis and multivariable modelling was not superior to CA19-9 alone in cross-sectional analysis. Within six months to diagnosis, CA19-9 (AUC = 0.92) outperformed the multivariable model (AUC = 0.81) at a cross-sectional level. At diagnosis, CA19-9 (AUC = 0.995) and the model (AUC = 0.977) performed similarly. Longitudinal analysis revealed increases in CA19-9 up to two years to diagnosis which indicates a window of opportunity for early detection of PDAC.

Place, publisher, year, edition, pages
MDPI, 2022. Vol. 23, no 21, article id 12969
Keywords [en]
analysis, biomarkers, carcinoma, early detection of cancer, pancreatic ductal, tumor, tumor microenvironment
National Category
Cancer and Oncology
Research subject
Surgery
Identifiers
URN: urn:nbn:se:umu:diva-201220DOI: 10.3390/ijms232112969ISI: 000881359700001PubMedID: 36361759Scopus ID: 2-s2.0-85141870302OAI: oai:DiVA.org:umu-201220DiVA, id: diva2:1719582
Funder
Swedish Research Council, 2017-01531Swedish Research Council, 2016-02990Swedish Research Council, 2019-01690Swedish Research Council, 2017-00650The Kempe Foundations, JCK-1301Swedish Society of Medicine, SLS-890521Swedish Society of Medicine, SLS-786661Region Västerbotten, RV-930167Västerbotten County Council, VLL-643451Västerbotten County Council, VLL-832001Region Västerbotten, RV-583411Region Västerbotten, RV-549731Region Västerbotten, RV-841551Region Västerbotten, 930132Region Västerbotten, RV-930167Cancerforskningsfonden i Norrland, LP20-2257Cancerforskningsfonden i Norrland, LP18-2202Cancerforskningsfonden i Norrland, LP18-2192Cancerforskningsfonden i Norrland, LP21-2298Cancerforskningsfonden i Norrland, LP22-2332Sjöberg FoundationKnut and Alice Wallenberg Foundation, KAW 2015.0114Marianne and Marcus Wallenberg Foundation, MMW 2020.0189Swedish Cancer Society, CAN 2017/332Swedish Cancer Society, CAN 2017/827Swedish Cancer Society, CAN 2011/751Swedish Cancer Society, CAN 2016/643Swedish Cancer Society, 19 0273Swedish Cancer Society, 20 1339Available from: 2022-12-15 Created: 2022-12-15 Last updated: 2023-06-08Bibliographically approved

Open Access in DiVA

fulltext(1997 kB)144 downloads
File information
File name FULLTEXT01.pdfFile size 1997 kBChecksum SHA-512
438fcf6326314e569eb0a71108517e2d5ff4c6d12f2b46acf491123e2d37cca9d5e3ffe3359ca26f35349835c64202be819bf51ef2373dd89b449e66c938937f
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Mason, James E.Lundberg, ErikJonsson, PärNyström, HannaFranklin, OskarLundin, ChristinaAntti, HenrikSund, MalinÖhlund, Daniel

Search in DiVA

By author/editor
Mason, James E.Lundberg, ErikJonsson, PärNyström, HannaFranklin, OskarLundin, ChristinaAntti, HenrikSund, MalinÖhlund, Daniel
By organisation
OncologyWallenberg Centre for Molecular Medicine at Umeå University (WCMM)SurgeryDepartment of Chemistry
In the same journal
International Journal of Molecular Sciences
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 146 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 312 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf